Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03170115
Other study ID # ICAR trial
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date November 30, 2017
Est. completion date January 17, 2020

Study information

Verified date December 2020
Source Instituto Nacional de Cancer, Brazil
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The benefit of aspirin in cancer of the colon and rectum is already known. Recently, it was described its potential activity during chemoradiotherapy, with higher rate of tumor downstaging. Furthermore, induction chemotherapy followed by chemoradiation represents an attractive approach, with more favorable compliance and toxicity profiles. The aim of this study was to evaluate the efficacy of total neoadjuvant treatment and assess the efficacy and feasibility of aspirin use during chemoradiotherapy for high-risk rectal cancer.


Description:

Methods: This is a randomized trial to evaluate induction treatment with XELOX and Capecitabine-based chemoradiotherapy with or without aspirin in a high-risk population selected by MRI. High-risk will be defined by presence of at least one of the following criteria on high-resolution thin-slice MRI (3 mm): tumors extending to within 1 mm of, or beyond the mesorectal fascia; tumor extending 5 mm or more into perirectal fat; resectable cT4 tumors; lower third; nodal involvement; extramural vascular invasion. Random assignment of treatment will be stratified by MRI tumour regression grade. All the patients enrolled in the study will receive XELOX every 21 days for four cycles, unless unacceptable toxicity or progression is detected. After this treatment, patients will be randomized to receive Capecitabine-based chemoradiotherapy with aspirin or placebo (Capecitabine 850 mg/m² 5 days per week combined with radiotherapy with total dose of 50.4 Gy in 28 days). After 8-10 weeks, they will be evaluate by MRI. Patients with incomplete clinical response will be referred to immediate surgery and patients with complete clinical response will be managed with "watch and wait" approach. Patients with progression disease during the treatment phase will be withdrawn from the study and will receive their treatment according to the investigator's judgment. The sample size was calculated according to Simon's optimal two-stage design. Accordingly, 11 patients must be included in each group during the first stage and 20 during the second stage. A treatment regimen will be considered effective if more than 18 patients of the total 31 show downstaging (final analysis), reaching 80% power with an alpha of 0.05 level of significance.


Recruitment information / eligibility

Status Terminated
Enrollment 25
Est. completion date January 17, 2020
Est. primary completion date January 17, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of mid or low rectum 2. Locally advanced rectal cancer with one of the high-risk factors confirmed by high-resolution thin-slice Magnetic resonance image (3 mm) - tumors extending to within 1 mm of, or beyond the mesorectal fascia; - tumor extending 5 mm or more into perirectal fat; - resectable cT4 tumors; - lower third; - nodal involvement; - extramural vascular invasion 3. ECOG performance status of 0-2 4. An informed consent has been signed by the patient Exclusion Criteria: 1. Upper rectal cancer 2. Metastatic disease 3. The patient received any previous therapy for colorectal cancer or another malignancy 4. Other malignant tumours within the last 5 years except cervical carcinoma in situ and basal cell carcinoma of the skin 5. Previous thromboembolic or haemorrhagic events within 6 months prior to registration 6. Patients with malabsorption syndrome or difficulties in swallowing 7. The patient has severe underlying diseases or poor condition to receive chemotherapy or radiotherapy 8. Pregnant of breastfeeding women 9. The patient who participate in another clinical trial, or receives any drug for the trial 10. Uncontrolled peripheral neuropathy (more than grade 2) 11. Active gastrointestinal bleeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Aspirin
chemoradiotherapy with capecitabine and aspirin Aspirin daily during chemoradiotherapy
Placebo Oral Tablet
chemoradiotherapy with capecitabine and placebo Placebo daily during chemoradiotherapy

Locations

Country Name City State
Brazil INCA- Instituto Nacional de Câncer Rio de Janeiro

Sponsors (1)

Lead Sponsor Collaborator
Instituto Nacional de Cancer, Brazil

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor downstaging after induction chemotherapy followed by chemoradiotherapy with or without aspirin This will be assessed by MR imaging 8-10 weeks after chemoradiotherapy and it will be considered tumor downstaging if mrTRG 1 to 3 8-10 weeks after chemoradiotherapy
Secondary Radiological Tumor response rate after induction chemotherapy This will be assessed by MR imaging after induction chemotherapy 3-4 weeks after last induction chemotherapy
Secondary Pathological Tumor response rate Amount of tumor regression after surgery according to the guideline including Mandard 10-12 weeks after chemoradiotherapy
Secondary Pathologic complete response it will be defined as the absence of residual invasive cancer on pathological evaluation of the complete resected rectal specimen 8-10 weeks after chemoradiotherapy
Secondary Disease-free survival defined as the time from surgery to relapse or death, whichever occurred first 3 years
Secondary Overall survival defined as the time from surgery to death, whichever occurred first 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03671226 - Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center N/A
Completed NCT01973673 - Healthy Bones Study N/A
Completed NCT01876927 - Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer Phase 2
Terminated NCT03295942 - A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors Phase 1
Completed NCT03238027 - A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors Phase 1
Recruiting NCT04260802 - A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers Phase 1/Phase 2
Completed NCT02823652 - Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer N/A
Completed NCT02227082 - Olaparib and Radiotherapy in Inoperable Breast Cancer Phase 1
Recruiting NCT01871363 - Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer Phase 2
Completed NCT01847001 - Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy Phase 2
Recruiting NCT04749108 - Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma Phase 2/Phase 3
Terminated NCT01836432 - Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Phase 3
Recruiting NCT01675999 - Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer Phase 2
Completed NCT01325558 - A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT01333709 - Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma Phase 2
Withdrawn NCT03849742 - Ride to Care - Quality of Life With Transportation for RT N/A
Active, not recruiting NCT03856060 - Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits N/A
Completed NCT04186884 - Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings
Recruiting NCT04112836 - Pancreatic Cancer Malnutrition and Pancreatic Exocrine Insufficiency in the Course of Chemotherapy in Unresectable Pancreatic Cancer
Not yet recruiting NCT03051152 - D1 Versus D2 Lymphadenectomy in High Risk Elderly With Gastric Adenocarcinoma N/A